Table 2.
Clinical and preclinical trials with target therapies in T-cell acute lymphoblastic leukemia.
| Type of study | Molecule | Reference |
|---|---|---|
| NOTCH1 INHIBITORS | ||
| Clinical, phase 1 | MK-0752 | (92) |
| Preclinical | PF-03084014 + DEX | (93) |
| Clinical | PF-03084014 | (94) |
| Clinical, phase 1b/2 | Crenigacestat (LY3039478) + Dex | NCT02518113 |
| Clinical, phase 1 | BMS-906024 alone or + DEX | NCT01363817 |
| Clinical, phase 1 | BMS-906024 | (95) |
| Clinical, phase 1 | MK0752-013 | NCT00100152 |
| Clinical, phase 1/2 | RO4929097 | NCT01088763 |
| CDK4/6 INHIBITORS | ||
| Preclinical | LEE011 + a panel of drugs | (96) |
| Clinical, phase 1 | Palbociclib + CT | NCT03792256/ AINV18P1 |
| PI3K/mTOR DUAL INHIBITORS | ||
| Preclinical | NVP-BEZ325/ Dactolisib | (97) |
| Clinical, phase 1 | NVP-BEZ325/ Dactolisib | NCT01756118 |
| Clinical, phase 1 | NVP-BKM120 | (98) |
| mTOR INHIBITORS | ||
| Clinical, phase 1 | Everolimus (RAD001) + CT | NCT01523977 |
| Clinical, phase I/II | Everolimus + HyperCVAD | (99) |
| Clinical, phase I | Temsirolimus (CCI799) + UK ALL R3 (Dex+Mitox+VCR+pegAsp) | (100) |
| Clinical, phase I | Everolimus + CT (VCR, PDN, peg Asp, Doxo) | (101) |
| Clinical, phase II | Sapanisertib | NCT02484430 |
| Clinical, phase 1 | Sirolimus + HyperCVAD | NCT01184885 |
| Clinical, phase 1 | Temsirolimus + VP16 + CTX+ DEX | NCT01614197 |
| Clinical, phase 1 | Everolimus + Nelarabina+ CTX+ VP16 | NCT03328104 |
| TK INHIBITORS | ||
| Clinical, phase 1/2 | Ruxolitinib (doses ranging from 10–80 mg) + L-ASP, VCR, and PDN | NCT03613428 |
| Preclinical | Imatinib or Dasatinib or Nilotinib | (102) |
| Clinical | Imatinib + CT | NCT00049569 |
| HDAC INHIBITORS (EPIGENETIC REGULATORS) | ||
| Clinical | Chidamide + CT | NCT03564704 |
| BCL2 inhibitors | ||
| Clinical | Venetoclax + CT | (103) |
| Clinical, phase 1/2 | Venetoclax + low intensity CT | NCT03808610 |
| Clinical, phase 1b/2 | Venetoclax + Vincristine | NCT03504644 |
CT, chemotherapy; Dex, dexamethasone; VCR, vincristine, Mitox, mitoxantrone; Asp, asparaginase; Doxo, doxorubicine; VP16, etoposide; CTX, cyclophosphamide; PDN, prednisone; TK, tyrosine kinase; HDAC, histone deacetylase.